Synedica Tirzepatide 40mg Injection - Dual GLP-1/GIP Support

Synedica Tirzepatide 40mg – is a dual-action incretin mimetic peptide targeting both GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1) receptors. Engineered for high-potency and long-lasting activity, it is ideal for advanced research into fat loss, insulin sensitivity, and type 2 diabetes treatment pathways,Manufactured by Synedica under GMP-certified conditions, this high-purity 40mg peptide offers researchers a reliable compound for studying metabolic optimization and weight regulation through dual receptor stimulation. It is trusted by research labs seeking consistency and performance in cutting-edge studies.

Key Features:

• Dual GLP-1 and GIP receptor agonist
• 40mg per vial – potent formulation
• Research-grade quality from Synedica

How to Use Synedica Tirzepatide:
Form: Injectable peptide

Dosage: Start with 0.5 mg per week, gradually increase to 2.5–5 mg per week as tolerated

Cycle Length: 8–16 weeks with a 4-week break after each cycle

Administration: Subcutaneous injection, once a week

How It Works:

• GIP Agonism: Increases insulin secretion and enhances metabolic efficiency.
• GLP-1 Agonism: Reduces appetite, slows gastric emptying, and improves blood sugar control.

Both of these actions help to reduce body fat while enhancing overall metabolic function.

Recommended Stacks:

Synedica Semaglutide for additional appetite control and fat loss

Hyge Tirzepatide or VLS Tirzepatide for a gradual transition post-cycle

Retatrutide or Synedica Retatutide for more aggressive fat loss